IDEC – The Business: Corporate Info

But we never gave up the dream of developing an antibody attached to a radioisotope for delivering targeted radiation.

Now with ZEVALIN™ (Ibritumomab Tiuxetan) which is currently being reviewed for marketing authorization by the U.S. Food and Drug Administration, we’re closer to realizing our dream of a “hot” antibody for the treatment of certain types of B-cell NHL.

I invite you to explore IDEC’s other “dreams.” Learn about the next generation of investigational agents we are striving to develop in cancer and autoimmune diseases. And discover our dedicated employees, courageous patients, committed partners, and innovative products and technologies.

I hope your visit to IDEC’s website will leave you with one indelible impression: never stop dreaming. And when others laugh at your dreams, thank them. Then get back to work and make your dreams of today the realities of tomorrow.

William H. Rastetter, Ph.D.
Chairman, Chief Executive Officer and President